European Association for the Study of Diabetes (EASD) 2001 Meeting

Diabetes Care

Volumn 25, Issue 7, 2002, Pages 1229-1236

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALT 946; AMINOGUANIDINE; OCTREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN INHIBITOR; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLYCOGEN SYNTHESIS; HUMAN; HYPERCALCEMIA; MEDICAL RESEARCH; METABOLIC DISORDER; NONHUMAN; OBESITY; POSTPRANDIAL STATE; ARTERIOSCLEROSIS; EUROPE; HEALTH CARE ORGANIZATION; HYPERGLYCEMIA; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; RISK FACTOR; T LYMPHOCYTE;

ARTERIOSCLEROSIS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; EUROPE; HUMANS; HYPERGLYCEMIA; PRIMARY PREVENTION; RISK FACTORS; SOCIETIES, SCIENTIFIC; T-LYMPHOCYTES;

EID: 0036636851     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.7.1229     Document Type: Conference Paper

References (39)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease: The Framingham Study. JAMA 241:2035-2038, 1979
2. Lehto S, Ronnemaa T, Pyorala K, Laakso M: Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol 19:1014-1019, 1999
3. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268, 1995
4. Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study (UKPDS 35). BMJ 321:405-412, 2000
5. The DECODE study group/European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999
6. Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD: Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 22:1262-1265, 1999
7. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
8. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, Schwanebeck U, Julius U: Diabetes Intervention Study: multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 14:308-317, 1991
9. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R: Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 31: 889-891, 1988
10. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95:1783-1790, 1997
11. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146-154, 1999
12. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790, 2000
13. Ceriello A, Bortolotti N, Crescentini A, Motz E, Lizzio S, Russo A, Ezsol Z, Tonutti L, Taboga C: Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 28:329-333, 1998
14. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, Taboga C: Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 21:1529-1533, 1998
15. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C: Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 48:1503-1508, 1999
16. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
17. Service FJ, Nelson RL: Characteristics of glycemic stability. Diabetes Care 3:58-62, 1980
18. Beisswenger PJ, Healy JC, Shultz EK: Glycosylated serum proteins and glycosylated hemoglobin in the assessment of glycemic control in insulin-dependent and non-insulin-dependent diabetes mellitus. Metabolism 42:989-992, 1993
19. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 (Suppl. 2):B21-B29, 2000
20. Teno S, Uto Y, Nagashima H, Endoh Y, Iwamoto Y, Omori Y, Takizawa T: Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 23:1401-1406, 2000
21. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamada T: 1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18:1156-1159, 1995
22. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD, Szwergold BS: α-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24:726-732, 2001
23. Beisswenger PJ, Szwergold BS, Yeo KT: Glycated proteins in diabetes. Clin Lab Med 21:53-78, 2001
24. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group: Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 317: 371-375, 1998
25. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42:1050-1054, 1999
26. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240, 1999
27. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322:15-18, 2001
28. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G: Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29:41-49, 1980
29. Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 34:891-898, 1991
30. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
31. Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J: Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland: study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 42:793-801, 1999
32. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose toleranc. N Engl J Med 344:1343-1350, 2001
33. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103:1191-1193, 2001
34. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, Kopolovic Y, Wick G, Shoenfeld Y, Harats D: Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138:147-152, 1998
35. George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, Levkovitz H, Shaish A, Goldberg I, Kopolovic J, Harats D, Shoenfeld Y: Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 98:1108-1115, 1998
36. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum JL: Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105:1731-1740, 2000
37. Bellush LL, Doublier S, Holland AN, Striker LJ, Striker GE, Kopchick JJ: Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology 141:163-168, 2000
38. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268, 2001
39. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME: Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44:108-114, 2001